Novartis gains breast cancer indication in Canada
This article was originally published in Scrip
Executive Summary
Health Canada has granted approval to Novartis to market Afinitor (everolimus) as a treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after recurrence or progression following treatment with letrozole or anastrozole.